H.R. 5139 (the 'EPIPEN Act') inserts parallel requirements into the Public Health Service Act, ERISA, and the Internal Revenue Code to change how health plans cover epinephrine delivery systems. The bill forces plans and issuers to cover FDA‑approved epinephrine delivery devices and constrains patient out-of-pocket exposure through statutory rules.
For plan sponsors, issuers, and benefits professionals this is a targeted, near-term compliance obligation: it alters what plans must cover, how copays/counting toward limits work, and how pharmacy channels and plan documents must be revised to reflect the new coverage floor.
At a Glance
What It Does
The bill requires coverage of FDA‑approved epinephrine delivery systems and bars plans from applying deductibles to those products. It caps cost sharing at $60 per package of two delivery systems (or equivalent) and requires any patient payments under that cap to count toward the plan’s deductible and out‑of‑pocket maximum.
Who It Affects
Group health plans (subject to ERISA and the Internal Revenue Code) and health insurance issuers offering group or individual coverage under the PHSA. Pharmacy benefit managers, plan sponsors, and employers that administer or fund health benefits will need to change formularies, benefit designs, and vendor contracts.
Why It Matters
The bill creates a unified federal floor for epinephrine access across major federal statutes, directly limiting patient cost exposure for life‑saving devices. That change forces immediate operational adjustments for plan administrators and could shift costs across plan sponsors, issuers, and drug manufacturers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The EPIPEN Act adds new statutory sections to three federal frameworks so the same basic rule applies to most private coverage: plans must cover FDA‑approved devices used to deliver epinephrine (the term includes auto‑injectors, nasal sprays, and sublingual systems) and they cannot make patients satisfy a deductible before obtaining them. The bill also places a firm dollar cap on permitted cost sharing and says any amount the patient pays under that cap must count toward the plan’s deductible and out‑of‑pocket maximum.
Operationally, the change is straightforward in concept but material in execution. Insurers and plan administrators must update plan documents, pharmacy benefit formularies, point‑of‑sale systems, and member communications to implement zero deductibles and to limit pharmacy copays to the statutory ceiling for the defined package size.
Pharmacy claims systems will need to recognize the billing unit specified by the law (a package of two delivery systems or an equivalent) and apply the capped patient cost at the point of sale.Because the bill inserts mirror provisions into the PHSA, ERISA, and the tax code, it creates a consistent federal requirement across insured and self‑funded plans while preserving standard network rules: plans with provider networks can still treat out‑of‑network fills differently and may impose higher cost sharing for out‑of‑network providers. The statute also includes an explicit definition of covered products that ties coverage to FDA approval, which limits the rule to regulated devices rather than broader categories of allergy care.The statute’s effective date is tied to plan years beginning on or after January 1, 2026.
That gives plan sponsors a finite implementation window but also concentrates the operational burden into the annual plan‑year change process (formularies, PBM contracts, consumer disclosures). Compliance work will largely fall on benefits teams, insurers, PBMs, and pharmacy operations rather than on clinical staff, but it will require coordination across those vendors and systems.
The Five Things You Need to Know
The bill bars plans from applying any deductible to epinephrine delivery systems.
Cost sharing is capped at $60 per package of two delivery systems (or equivalent).
Patient payments under that cap must be counted toward the plan’s deductible and out‑of‑pocket maximum.
The statutory definition limits coverage to FDA‑approved delivery systems (auto‑injectors, nasal sprays, sublingual systems).
The new rules are added in three places—PHSA (new section 2799A‑11), ERISA (new section 726), and the Internal Revenue Code (new section 9826)—creating a uniform federal requirement.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Coverage floor and patient cost limits for insured plans
This provision applies to health insurance issuers offering group and individual coverage under the Public Health Service Act framework. It requires issuers to include epinephrine delivery systems on their covered products list without applying deductibles and limits patient cost sharing to the $60 per two‑pack ceiling. Practically, insurers issuing individual and fully insured group policies will need to amend plan contracts, update member materials, and coordinate with pharmacy networks to ensure point‑of‑sale charges reflect the statutory cap.
Requirement for group health plans, including self‑funded plans
By adding a mirror provision to ERISA, the bill reaches employer‑sponsored self‑funded plans that otherwise would not be governed by state insurance rules. Plan administrators must revise SPD/plan documents and vendor agreements to implement the deductible prohibition and capped cost sharing. Because ERISA governs remedies and preemption, this insertion also standardizes federal enforcement and limits state‑by‑state variation for employer plans.
Tax code alignment with benefit rules for employer plans
The Internal Revenue Code amendment aligns tax treatment with the coverage mandate so that qualified employer plans are required to comply for tax‑favored benefits. This reduces an administrative inconsistency where a rule applied only under insurance law might have left some tax‑preferred employer arrangements untreated. Payroll, tax, and benefits teams will need to confirm that plan operations and tax reporting reflect the new coverage standard.
Applies to plan years beginning on or after January 1, 2026
The statute ties compliance to plan year start dates, creating a clear compliance milestone. Organizations with non‑calendar plan years must map their plan year start to January 1, 2026, or later for applicability. That timing funnels changes into the normal annual plan amendment cycle but compresses work for entities with plan years beginning in early 2026.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with severe allergies who use epinephrine delivery systems — they face lower at‑the‑counter cost and no deductible barriers at fill, improving immediate access to life‑saving devices.
- Parents and caregivers who buy epinephrine devices for children — the per‑package cap reduces the out‑of‑pocket spike when replacing expired or used devices.
- Insurers and benefits consultants focused on predictable benefit design — the bill creates a uniform federal rule they can operationalize across book of business rather than managing a patchwork of state mandates.
Who Bears the Cost
- Employers sponsoring self‑funded plans — eliminating deductibles and capping cost sharing will likely increase plan pharmacy spend and could raise contributions or premiums over time.
- Health insurers and PBMs — they must reconfigure contracts, claims adjudication, and point‑of‑sale pricing logic to apply the capped cost per specified package size.
- Manufacturers of epinephrine delivery systems — reduced patient price resistance may shift volume and pricing pressure; manufacturers could face political and commercial pressure to justify list prices.
Key Issues
The Core Tension
The central dilemma is balancing immediate patient affordability for life‑saving epinephrine devices against the downstream cost allocation: the bill reduces point‑of‑sale barriers for patients but shifts financial burden to plans, employers, insurers, or taxpayers, creating trade‑offs between access and the long‑term distribution of healthcare costs.
The bill neatly defines the covered products by tying coverage to FDA approval, but that choice creates implementation ambiguity in two areas: first, how to treat combination products or new formulations whose FDA labeling differs (for example, single‑use versus multi‑pack configurations), and second, how to operationalize the statutory "package of 2 delivery systems (or the equivalent)" across pharmacy NDCs and billing units. Pharmacy systems and PBMs will need precise mapping rules to ensure the $60 cap applies correctly and consistently.
Another tension is the law’s allowance for plans to impose higher cost sharing for out‑of‑network providers. That preserves network design levers for plans but risks leaving some patients with higher costs when their preferred pharmacy or provider is outside the network — especially in areas with limited in‑network pharmacy access.
Finally, while counting patient payments toward deductibles and out‑of‑pocket maxima improves consumer protections, it transfers more spend to the plan level; absent offsetting measures, that could push costs into premiums or employer contributions, creating indirect effects the statute does not address.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.